TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

PURPOSE: To infer the prognostic value of simultaneous androgen receptor (AR) and TP53 profiling in liquid biopsies from metastatic castration-resistant prostate cancer (mCRPC) patients starting a new line of AR signalling inhibitors (ARSi). EXPERIMENTAL DESIGN: Between March 2014 and April 2017, we...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: De Laere, Bram, Oeyen, Steffi, Mayrhofer, Markus, Whitington, Tom, van Dam, Pieter-Jan, Van Oyen, Peter, Ghysel, Christophe, Ampe, Jozef, Ost, Piet, Demey, Wim, Hoekx, Lucien, Schrijvers, Dirk, Brouwers, Barbara, Lybaert, Willem, Everaert, Els, De Maeseneer, Daan, Strijbos, Michiel, Bols, Alain, Fransis, Karen, Beije, Nick, de Kruijff, Inge, van Dam, Valerie, Brouwer, Anja, Goossens, Dirk, Heyrman, Lien, Van den Eynden, Gert, Rutten, Annemie, Del Favero, Jurgen, Rantalainen, Mattias, Rajan, Prabhakar, Sleijfer, Stefan, Ullén, Anders, Yachnin, Jeffrey, Grönberg, Henrik, Van Laere, Steven, Lindberg, Johan, Dirix, Luc
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6330086/
https://ncbi.nlm.nih.gov/pubmed/30209161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1943
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares